StockWatch
·

5paisa Capital Ltd Q2 FY27 Results

5PAISAQ2 FY27 Results
Filing
Result:Weak· Market: Flat#Margin squeeze

Outlook: Cautiously Optimistic · Guidance: None

MetricValue (₹ Cr)Q1 FY27Q2 FY26
Revenue86.422.2%11.8%
Total Income86.462.2%11.8%
Expenditure77.005.6%19.3%
PBT9.4638.8%25.7%
Net Profit7.0639.0%25.6%
OPM25.20%4.31pp4.51pp
NPM8.16%4.93pp4.11pp
EPS1.5540.4%49.0%
View full financials

Net profit fell 25.5% YoY with NPM compressing to 8.2% from 12.3% even as revenue grew 11.8%, as finance cost and depreciation outpaced core broking cost growth — a clear below-par profit outcome for the sector despite top-line growth.

5PAISA · Q2 FY27 · THE VERDICT

Revenue Up, Profits Down 26%—Execution Risk on the App Bet

5paisa delivered 12% revenue growth but PAT collapsed 26% YoY, signaling aggressive investment spend and soft market conditions. The quarter's real story is whether the app rebuild, AI features, and Trendlyne acquisition can drive margin recovery—or if near-term profitability remains under pressure.

23 Oct 2026 · 6 min read
Revenue

₹86.5 Cr

+11.8% YoY, customer growth +81.6K

Net Profit

₹7.1 Cr

-25.5% YoY, -39% QoQ

Operating Margin

25.2%

Compressed by capex + soft market

Balance Sheet

₹1,136 Cr net worth

+₹486 Cr from rights issue

The headline read is a paradox: revenue up 12%, net profit down 26%. The gap reveals where 5paisa's money went this quarter and the stakes of what comes next.

Why profit fell despite revenue growth

PAT declined ₹4.5 Cr quarter-on-quarter (39% drop) and ₹2.6 Cr year-on-year (26% decline) while revenue grew. Management attributed the squeeze to two factors: heavy product investment spend (app development, AI features, Trendlyne integration prep) and soft derivatives market post-cash rollout. The company capitalized ₹62 million in app development costs in Q2 alone, which will amortize forward and pressure margins for "several years," though no schedule was disclosed. This choice—to invest aggressively while market headwinds blow—signals confidence in the product roadmap but leaves near-term profitability vulnerable.

₹ Crore
04.338.6612.9911.6Q1 FY27 PAT7.1Q2 FY27 PAT8.2Net Profit Margin
PAT down ₹4.5 Cr QoQ. Capex and soft market are cited; recovery timeline not quantified.

Management claims vs. what holds up

Grading management's key assertions against the data

New app with AI features driving engagement

Unverified

Ask 5paisa and AI portfolio tools live for only weeks to a few months. Management admitted 'it is a little early day.' Engagement metrics and user retention gains not disclosed.

95% of customers open accounts DIY

Supported

Aligns with stated digital-first strategy and 53.4L customer base with 81.6K new adds this quarter. Demonstrates product appeal.

Soft quarter due to derivatives volume drop

Supported

Derivatives volumes post-cash rollout were cyclical market headwind. Average daily NSE turnover ₹2.59T reflects industry-wide slowdown, not 5paisa-specific operational issue.

Best years still ahead

Overstated

No quantified forward targets. PAT down 26% YoY. Product roadmap ambitious (new app, AI, Trendlyne, AlgoSpace) but execution unproven and timelines vague. Depends entirely on speculative product bets.

What changed on this call

  • Balance sheet upgraded materially: Net worth jumped ₹486 Cr post-rights issue (from ₹650 Cr in Mar 2026 to ₹1,136 Cr now), enabling debt repayment (₹150 Cr planned) and product investment (₹88 Cr envelope). Funding book at ₹480 Cr average with safe spreads.

  • Product roadmap expanded with specificity: Rebuilt app with new OMS/RMS, AI assistant (Ask 5paisa), algo trading (AlgoSpace), Xstreme APIs, co-location, and Trendlyne acquisition (board approved end-July, formal closure pending). Material upgrade from prior call's vague 'product upgrades.'

  • Near-term profitability deteriorated sharply: PAT down 39% QoQ and 25.5% YoY despite 11.8% revenue growth. Severity and expected recovery timeline not addressed in prior call or disclosed now.

  • No quantified guidance, again: Management reiterated its refusal to provide revenue, margin, or growth targets. Focus stated as 'user engagement, adoption, monetization' but no milestones. Makes accountability difficult.

The bull-bear ledger

  • Balance sheet now fortress-like: ₹1,136 Cr net worth funds 3+ years of aggressive product investment without dilution or debt.

  • Customer growth steady: 81.6K new accounts this quarter, 53.4L total, with 95% DIY signup rate proving product-led traction.

  • Product roadmap credible in scope: New app, AI, algo trading, Trendlyne research moat, co-location—diversification away from vanilla broking.

  • PAT collapse unaddressed: Down 26% YoY despite 12% revenue growth. No margin recovery plan or timeline disclosed. Capex amortization drag to persist years.

  • Execution risk very high: New features (app, AI, Trendlyne) live only weeks to months. Engagement metrics withheld. Management framed product viability as 'too early to assess.'

  • Market headwinds cyclical but persistent: Derivatives volumes soft post-cash rollout. No clarity on demand recovery timeline or whether slowdown masks product weakness.

  • Trendlyne integration path unclear: Board approved end-July; formal closure still pending. Whether it merges, stays subsidiary, or how synergies materialize—all deferred.

Risks, ranked by how much they should concern a holder

What could break the narrative, in order of severity for equity holders

Product execution fails or takes longer than expected

HIGH

New app, AI, Trendlyne are the only margin recovery bets. If adoption is slow, engagement doesn't materialize, or integration stumbles, near-term margin pressure persists and long-term thesis breaks. Currently unquantified and unproven (features days/weeks old).

PAT continues to decline while investments continue

HIGH

If Q3/Q4 see further PAT declines without visibility to product monetization, confidence will crack. Management has no margin targets to defend against; quarterly P&L becomes the only scorecard.

Derivatives slowdown is structural, not cyclical

MEDIUM

Underlying assumption is that cash rollout downturn is temporary and retail participation will recover. If derivatives volumes remain suppressed, revenue growth headwind persists and capex ROI timeline extends.

Trendlyne closure delayed further or integration disappoints

MEDIUM

Still pending formal close. Delays would postpone revenue synergy and proof-of-concept for M&A strategy. Weak integration would undermine confidence in adjacent expansion.

Competitive intensity rises on product quality

MEDIUM

Discount broking space crowded (Zerodha, Shoonya, others). 5paisa's app/AI differentiation must hold or margin recovery narrative fails. No moat proof yet.

How the street is positioned

Price action: The day-1 move was muted: +0.25% to ₹344.4, barely holding the pre-result close of ₹344.15. Minimal conviction either way. The market's restraint makes sense—revenue growth is real, but profit collapse invites caution on near-term execution. Stock now sits at ₹325, below the 20/50/200-day SMAs (331.61/345.76/336.38), suggesting it's lost momentum post-result.

Valuation context: The stock is down 57.19% from its all-time high of ₹759.1, but up 32.65% from the 52-week low (₹245). It sits roughly at the 200-day MA level, not deeply cheap but not bouncing either. RSI at 43.1 is neutral—no oversold capitulation, no overbought euphoria.

Institutional flows: FII ownership rose from 12.41% (Q4 FY26) to 15.11% (Q1 FY27), a +2.7pp gain—meaningful buying during the quarters bracketing this result. Promoters also bought, increasing stake from 32.77% to 36.50% (+3.73pp). DII remained near zero. The insider and FII buying signals confidence in the long-term bet, but the muted day-1 price reaction shows the street isn't rushing to chase it.

The institution positioning and insider buying do not contradict the fundamental read of execution risk—they align with a high-risk, high-reward thesis. FII and promoters are betting on the product roadmap panning out. But the stock's technical weakness (below key SMAs) and minimal post-result pop suggest most of the market is skeptical or waiting for proof.

The debate

What to watch next
  • 1 · Q3 PAT and margin trajectory

    Is the decline stabilizing or accelerating? Does PAT reach ₹7–₹8 Cr range (steady state) or drop further? Monitor the quarterly amortization schedule—if capex continues at ₹50–₹100M/Q, margins stay depressed. Management must quantify the recovery timeline, not just say 'wait and see.'

  • 2 · Trendlyne formal closure and integration announcements

    When does the acquisition close? Does it merge into the 5paisa app or remain separate? What are the early user engagement and cross-sell metrics? Any synergy quantification (revenue uplift, cost savings, customer lifetime value gains)? This will tell whether the deal is a strategic win or a distraction.

  • 3 · New app and AI feature adoption metrics

    Management said features are 'only weeks to months old'—Q3/Q4 should show early traction signals. Monitor: monthly active users on the new app, Ask 5paisa engagement (daily active users, queries answered, conversion to trade), customer acquisition cost (CAC), and retention cohorts. If these metrics are silent, it's a warning sign.

5paisa had a steady quarter—not a step-change. Revenue grew 12%, but profit fell 26%, and the company chose to invest instead of defend margins. That's a credible strategic choice given a fortress balance sheet, but it's also an admission that near-term earnings will be messy. The long-term bet on product, AI, and Trendlyne is sound; the near-term proof is absent.

For holders, the game is one of patience: expect continued pressure on PAT through H2 FY27, and demand that management quantify margin recovery timelines and product adoption milestones in the next call. For new entrants, wait for proof that the app and AI are driving user retention and monetization; ₹325 is fairly priced at current execution risk.

The number to track from here is organic net profit (PAT minus any one-time items), not revenue. If capex-driven PAT decline persists into Q4 without visibility to margin recovery, confidence will erode, and the stock will re-test the ₹250–₹270 range.

Informational and educational content only. Not investment advice.